摘要
急性冠脉综合征(ACS)发生发展的实质是血栓事件,抗血小板治疗是ACS治疗的基石,阿司匹林联合氯吡格雷是经典的双联抗血小板治疗方案。新型P2Y12受体抑制剂(普拉格雷或替格瑞洛)与氯吡格雷相比在改善缺血和预后方面具有更多优势,但也增加了出血风险。本文拟对近几年ACS患者口服抗血小板药物治疗研究进展做一综述。
The essence of occurance and development of acute coronary syndrome （ACS） is the thrombotic events. The antiplatelet therapy is the cornerstone of ACS treatment. The combination of aspirin and clopidogrel is a classic dual anti-platelet therapy. The novel P2Y12 receptor inhibitor （prasugrel or tigriol）, on the one hand, has more advantages in the improvement of ischemia and prognosis than clopidogrel does, but on the other hand it increases the risk of bleeding. The aim of this paper is to review the research progress in oral anti-platelet drugs therapy in ACS patients.
出处
《实用医院临床杂志》
2017年第1期26-29,共4页
Practical Journal of Clinical Medicine
